You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

 

Online download statistics by month:

Online download statistics by month: July 2021 to March 2024

AbstractFullPdf
Jul 2021283283102
Aug 202132132683
Sep 202120920962
Oct 202117817839
Nov 202114314241
Dec 202111411518
Jan 202211611836
Feb 2022939536
Mar 2022828440
Apr 2022667138
May 202213113351
Jun 2022808328
Jul 2022767613
Aug 202210310332
Sep 2022909026
Oct 2022879127
Nov 2022656516
Dec 2022717118
Jan 2023767615
Feb 202310110135
Mar 2023656619
Apr 2023606013
May 2023808015
Jun 2023858520
Jul 2023626222
Aug 2023555515
Sep 2023606118
Oct 2023585815
Nov 2023646418
Dec 2023535517
Jan 2024414215
Feb 2024636334
Mar 2024889050
Total331933511027